Based on the pro-tumorigenic effects of CD95 in several tumor types, neutralization of CD95L is currently being tested as an anti-cancer strategy.45, 46 The results presented in the current report raise the question whether CD95-neutralizing therapy could interfere with senescence induction in situ, and if so, whether this may influence tumor growth and/or metastasis. The gene discussed is FAS; the disease is cancer.